Papers & Publications

MSU doctoral student seeking a cure for her son’s rare disorder wins fellowship

Monday Jun. 26th, 2017

A Montana State University doctoral student who is seeking a cure for her son’s rare genetic disorder has won a fellowship that will allow her to quit the predawn paper route she took to make ends meet and concentrate fully on her research.

Elizabeth “Tess” Corbin, a doctoral student from Bozeman in the Department of Chemistry and Biochemistry in MSU’s College of Letters and Science, has won a Ford Foundation Dissertation Fellowship

https://bozemanmagazine.com/news/2017/06/26/107787-msu-doctoral-student-seeking-a-cure-for-her


https://www.mthightech.org/news/montana-biotech-companies-to-watch-2020/#PurCell


Comments from collaborators:

  • “I am eager to apply the HEK supplement to my exosome producing HEK cells, and expect this will enable clinical trials for my work, by eliminating contamination issues.” 
    Dr. Matthew Hudson, Univ. of Delaware
  • “These chemically defined, customized supplements will provide a defined environment for the cell-based toxicology research being conducted in our lab and many others. The line of supplements being developed by PurCell Bio, promises to eliminate major sources of variability in research results, facilitating more precise and applicable results.” 
    Dr. Braulio Jimenez-Velez, Univ. of Puerto Rico
  • “These supplements will be especially helpful as applied to advanced technologies such as stem cell reprogramming and differentiation protocols, and cell-based protein production because they virtually eliminate the significant problem of potential contamination associated with use of serum and serum albumin in cell culture.” 
    Dr. Renee Reijo-Pera, Cal Poly
  • “…the chemically defined supplements to replace FBS in culture of cells used to produce exosomes, may eliminate major limitations to the production limitations of current FDA approved constructs like adeno-associated viral vectors for gene therapy but also the next generation of gene therapy biologics including extracellular vesicles.”
    Dr. Matthew Hudson, U of Delaware
  • “The line of supplements in development by PurCell Bio is a promising solution to many of the massive pain-points in the scientific and research communities related to FBS, including reproducibility and possibility of contamination, as well as signaling interference. We strongly believe that PurCell Bio offers a solution to numerous problems for different segments of the biotech industry.”                                                                                       
    Les Craig, Next Frontier Capital

References

  1. Optimization of chemically defined cell culture media – Replacing fetal bovine serum in mammalian in vitro methods. Valk et al., 2010. https://doi.org/10.1016/j.tiv.2010.03.016
  2. The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. Van der Valk et al., 2004. https://doi.org/10.1016/j.tiv.2003.08.009 
  3. PA 18-815 Opportunity announcement, NIH (2019). PA-18-815: Better Defining Growth Medium to Improve Reproducibility of Cell Culture (SBIR) (R43/R44 – Clinical Trial Not Allowed) (nih.gov)
  4. Comparative analysis of FBS containing media and serum free chemically defined media for adipose derived stem cells production. Kang et al., 2019. https://doi.org/10.1016/j.jcyt.2019.03.497 
Previous Article